Takeda in more trouble at home over recall of mislabeled vials

Japan's Takeda has gotten into more local hot water over the recall earlier this year of a lot of its Alinamin-F5 dietary supplement sold in Japan for vitamin B1 deficiency. The Osaka Pharmaceutical Manufacturers Association (OPMA) has suspended Takeda's activities as chair of the good manufacturing practice (GMP) committee, and vice-chair of the pharmaceutical laws and regulations committee for 6 months starting March 29 because of the incident, Pharmafile reports. In February, Takeda's contract manufacturer Nihon Pharmaceutical was ordered by the Osaka Prefectural Government to close down for 12 days after a box of vials were found in the market without labels. The company determined that a box containing samples was being used to determine the correct placement of the label on the outer box but "was mistakenly put into the actual manufacturing line of the real product." Takeda said it took the OPMA action very seriously and had instituted new procedures to make sure the same mistake was not made again. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.